TP53 and mantle cell lymphoma: AZD6738 demonstrated monotherapy activity in primary CLL patient-derived xenografts with 11q deletion (ATM-deficient) and 17p deletion (p53-deficient), as well as xenografts of ATM- and p53-deficient mantle cell lymphoma cell lines [139].